Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 3 6Phase 1/2 4Phase 4 2Phase NA 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Myeloid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Enoxaparin 5Bevacizumab 5Nivolumab 4Carboplatin 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3pembrolizumab 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × zanubrutinib × Clear all
NCT07169331 2025-12-19

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

BeOne Medicines

Phase 4 Recruiting
18 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
40 enrolled
LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡